{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Shen ZQ"],"funding":["Government of Jiangsu Province","National Natural Science Foundation of China"],"pubmed_abstract":["Immunotherapy targeting immune checkpoints has emerged as a promising strategy in cancer treatment; however, the heterogeneous and dynamic tumor microenvironment (TME) imposes critical constraints on therapeutic outcomes. Tryptophan 2,3-dioxygenase (TDO), often dysregulated in malignant tissues, plays a pivotal role in shaping an immunosuppressive milieu by depleting tryptophan, thereby hindering anti-tumor immune response. To counteract this immune evasion mechanism, we designed a novel indole-coordinated ruthenium(ii) arene complex (In-Ru), aimed at bolstering tumor immunotherapy and thwarting immune evasion by targeting TDO expression. Our findings reveal that In-Ru exerts markedly potent anti-proliferative effects against HepG2 cells. It achieves this by specifically localizing to the "],"journal":["Chemical science"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12308519"],"repository":["biostudies-literature"],"pubmed_title":["Novel tryptophan 2,3-dioxygenase-targeted ruthenium(ii)-indole complex activates immunotherapy <i>in vitro</i> and <i>in vivo</i>."],"pmcid":["PMC12308519"],"funding_grant_id":["22477062","22350001","KYCX24-1805","22077066"],"pubmed_authors":["Liu H","Wang P","Shen ZQ","Zhang Y","Liu HK","Ren M","Su Z","Guo B","Xue X","Dai X","Xu Y"],"additional_accession":[]},"is_claimable":false,"name":"Novel tryptophan 2,3-dioxygenase-targeted ruthenium(ii)-indole complex activates immunotherapy <i>in vitro</i> and <i>in vivo</i>.","description":"Immunotherapy targeting immune checkpoints has emerged as a promising strategy in cancer treatment; however, the heterogeneous and dynamic tumor microenvironment (TME) imposes critical constraints on therapeutic outcomes. Tryptophan 2,3-dioxygenase (TDO), often dysregulated in malignant tissues, plays a pivotal role in shaping an immunosuppressive milieu by depleting tryptophan, thereby hindering anti-tumor immune response. To counteract this immune evasion mechanism, we designed a novel indole-coordinated ruthenium(ii) arene complex (In-Ru), aimed at bolstering tumor immunotherapy and thwarting immune evasion by targeting TDO expression. Our findings reveal that In-Ru exerts markedly potent anti-proliferative effects against HepG2 cells. It achieves this by specifically localizing to the ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2026-05-28T02:17:14.77Z","creation":"2025-08-27T03:06:51.249Z"},"accession":"S-EPMC12308519","cross_references":{"pubmed":["40747318"],"doi":["10.1039/d5sc03778f"]}}